Drug price negotiation for ‘Tagrisso’ called off once again, brings controversy of special treatment for multinational pharma
The drug price negotiation for AstraZeneca Korea’s ‘Tagrisso,’ a treatment for non-small cell lung cancer with T790M mutations, has been called off once again, which raised controversy about special treatments on the multinational pharmaceutical company. It is the first time for a final negotiati...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
